Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Lignin utilization in mycelium-based biocomposites from recycled wood (LignoMBB)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Austria
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-11-01
End date: 2025-10-31
Duration (months): 24.0
Total project cost (EUR): 199440.96
EU funding (EUR): 199440.96
Participants: 1
Project status: SIGNED

We have reached a point where we have to use recycled wood, which is mostly contaminated, to a greater extent because there is a shortage of raw wood in the EU. At the same time, in pulp mills, we produce large amounts of lignin, however, use it mainly for energy purposes. LignoMBB is bringing technology for the production of mycelium-based biocomposites (MBB), during which recycled wood is decontaminated. Secondly, LignoMBB is using lignin, which is currently mainly used for energy and is understood as a by- or waste product, in order to achieve better mycelial growth on the developed substrate. I am the first to suggest enriching the substrate for the production of MBB with lignin, expecting that the addition of lignin will result in better mechanical properties of the MBB. LignoMBB develops materials only from recycled wood and lignin, i.e. it does not use agricultural residues, as is currently common practice, and does not endanger food security. At the same time, it finds application for large volumes of old contaminated wood, which is currently entering circulation. My first objective is to develop a technology for the material use of lignin and a substitution technology of agricultural residues in MBBs with lignin and recycled wood. Then, I will answer the questions: To which extent additional lignin in MBB is consumed by fungi? What are the limits of substrate enrichment by lignin? In accordance with the second objective, I will develop a novel MBB to be used in structural applications. At different stages of the MBB cycle, I will measure the VOC emissions because I am hypothesizing that the production process of MBB can act as bioremediation and decreases VOC emissions from materials. LignoMBB will be implemented at BOKU in Bio-Resources & Technologies Tulln group, where the emphasis is placed on cradle-to-cradle design and brings to this group methods of recycled wood decontamination and production of fully degradable MBB.

Keywords: composite material wood lignin mycelium decontamination
Characterization of the Mobility and Evolution of Non-Transmissible Plasmids (EvoPlas)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-07-01
End date: 2024-06-30
Duration (months): 24.0
Total project cost (EUR): 195914.88
EU funding (EUR): 195914.88
Participants: 1
Project status: CLOSED

Bacteria are extraordinarily adaptive organisms spread all over the globe and making up about half of the cells in our bodies. Their main source of novel functions is horizontal gene transfer, usually prompted by mobile genetic elements such as plasmids, that provide them with a wide range of traits. Plasmid conjugation is the main mechanism of dissemination of antimicrobial resistance (AMR), an increasingly important health problem. However, more than half of the plasmids found in bacterial genomes lack genes encoding conjugation functions and it is not known how they are transferred between cells. Since extensive data shows that many of these plasmids are transferred, it is important and urgent to study how this takes place to understand and predict their epidemiological patterns. EvoPlas has two main objectives. First, to unravel the mechanisms by which the putatively non-transmissible plasmids are transferred between cells, thereby showing the actual ability of plasmids to spread within populations. Second, to identify the evolutionary origins of non-transmissible plasmids and understand their stability in bacterial lineages. EvoPlas will use bioinformatics and experimental biology to leverage massive genomic data in order to unravel key aspects of bacterial evolution by horizontal gene transfer. It will additionally provide cutting-edge knowledge on the evolution of bacterial conjugation, novel insights into integrative mobile genetic elements and provide major advances on the understanding of how AMR spreads. At the later stages of EvoPlas, we will develop machine learning models of plasmid mobility to anticipate the dissemination of antimicrobial resistance genes. Hence, by combining my expertise in plasmid biology with the host lab’s expertise in big data and computational biology, EvoPlas has the potential to uncover new insights into bacterial and plasmid evolution and provide novel approaches to fight against the spread of AMR.

Keywords: plasmid biology antimicrobial resistance
Federate Learning and mUlti-party computation Techniques for prostatE cancer (FLUTE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Maintaining an innovative, sustainable and globally competitive health industry
Action type: Research and Innovation actions
Countries involved: France,Spain,Israel,Italy,United Kingdom,Belgium,Romania
Call: Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation (HORIZON-HLTH-2022-IND-13, 2022)
Start date: 2023-05-01
End date: 2026-04-30
Duration (months): 36.0
Total project cost (EUR): 6304750.0
EU funding (EUR): 6304750.0
Participants: 12
Project status: SIGNED

The FLUTE project will advance and scale up data-driven healthcare by developing novel methods for privacy-preserving cross-border utilization of data hubs. Advanced research will be performed to push the performance envelope of secure multi-party computation in Federated Learning, including the associated AI models and secure execution environments. The technical innovations will be integrated in a privacy-enforcing platform that will provide innovators with a provenly secure environment for federated healthcare AI solution development, testing and deployment, including the integration of real world health data from the data hubs and the generation and utilization of synthetic data. To maximize the impact, adoption and replicability of the results, the project will contribute to the global HL7 FHIR standard development, and create novel guidelines for GDPR-compliant cross-border Federated Learning in healthcare. To demonstrate the practical use and impact of the results, the project will integrate the FLUTE platform with health data hubs located in three different countries, use their data to develop a novel federated AI toolset for diagnosis of clinically significant prostate cancer and perform a multi-national clinical validation of its efficacy, which will help to improve predictions of aggressive prostate cancer while avoiding unnecessary biopsies, thus improving the welfare of patients and significantly reducing the associated costs. Team. The 11-strong consortium will include three clinical / data partners from three different countries, three technology SMEs, three technology research partners, a legal/ethics partner and a standards organization. Collaboration. In accordance with the priorities set by the European Commission, the project will target collaboration, cross-fertilization and synergies with related national and international European projects.

Keywords: federated learning,privacy enhancing technologies,secure multiparty computation,differential privacy,homomorphic encryption,privacy metrics,gdpr,privacy preserving cross border learning
A Novel Handheld Ultrasound Medical Imaging Probe: Prototyping, Initial Validation and Business Development (LucidWave)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Challenges
Action type: EIC actions
Countries involved: Belgium
Call: Medical Technology and Devices: from Lab to Patient (HORIZON-EIC-2021-TRANSITION-CHALLENGES-01, 2021)
Start date: 2022-07-01
End date: 2025-10-31
Duration (months): 40.0
Total project cost (EUR): 2427025.0
EU funding (EUR): 2427025.0
Participants: 1
Project status: SIGNED

The LucidWave Project introduces a low-cost, very capable, handheld ultrasound probe for medical imaging based on an entirely new ultrasound technology. It aims to provide a light, but powerful imaging tool to a wide range medical professionals for bed-side, point-of-care, office and operating room diagnostics. Doing so it will bring the well-known capabilities of classic ultrasound imaging closer and faster to the patient, helping not only radiologists to make better decisions, but also GP?s, nurses, veterinarians. Consequently, much time, costs and misdiagnosis will be saved for patient and physician. The project has to following objectives: (I) Starting at TRL 4, develop and deliver 2 full functional prototypes with all parts integrated into one slim device. The capabilities will largely surpass those of current handheld devices. (II) Validate the prototype?s performance in a clinical evaluation. Together with the foundations of a Quality Management System (ISO 13485), it will provide a head start for a later formal Clinical Validation according to the new Medical Device Regulation. (III) Build an entrepreneurial and complementary team by inviting entrepreneurs-in-residence. (IV) In preparation of a start-up a complete and quantified business plan will be created, building on a solid Value Proposition Canvas (incl. user-centric design) which is developed into a Business Model Canvas. LucidWave fits well into the EIC Transition Programme since it aims to develop a mature proof-of-concept (validated against state-of art) into a prototype ready for Clinical Validation and for scaling-up of the manufacturing. The technical part is complemented with a business strategy for a new and healthy start-up. It addresses one of the key challenges and priorities of Europe, i.e. to build a healthy society.

Keywords: ultrasonics,ultrasound,piezoelectric micromachined ultrasound transducer pmut,pocus,mems
Slab Plume Interactions in Deep Earth Regions (SPIDER)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: France,United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-12-01
End date: 2027-11-30
Duration (months): 24.0
Total project cost (EUR): 242260.56
EU funding (EUR): 242260.56
Participants: 2
Project status: SIGNED

Understanding mantle dynamics requires deep knowledge of plumes and slabs. Seismic tomography images reveal the existence of interacting slabs and plumes with very intricate shapes. This wide diversity of interacting slab-plume morphologies is indicative of their properties (strength, rheology, composition) and dynamics, although we still lack strong quantitative studies, most numerical models address slab or plume dynamics in isolation. The SPIDER project proposes to focus on slab-plume interactions, in order to decipher the effects of plume and slab properties on their geometry and dynamics. To do so, SPIDER will 1/ numerically model complex slab-plume interactions within a vigorously convecting mantle using the state-of-the-art code StagYY. The applicant will develop topological tools to automatically detect and time-track the plume and slab morphologies and properties; 2/ rigorously explore the effects of the rheological contrasts between slabs and plumes, magmatic-geochemical evolution and mantle melting on slab-plume interaction patterns; and 3/ systematically compare seismic tomography, magmatism and climatic observations in the very distinct Tonga-Samoa and Farallon-Yellowstone slab/plume systems with the characteristics and dynamics of model slab/plume interactions. This unprecedented effort to explain the diversity of observed slab-plume interactions will ultimately help to constrain mantle rheology and dynamics. The applicant will bring his experience in numerical modeling of subduction zone and plume dynamics to the Laboratoire de Géologie de Lyon, Terre, Planètes et Environnement (LGL-TPE, UCBL, France) and University College London, UK, where he will benefit from and contribute to world-leading expertise on the Earth’s mantle-lithosphere evolution in a stimulating intellectual environment. This project will reinforce his professional independence and knowledge diversity as he will become a key player in the geodynamic modeling domain.

Keywords: numerical modeling,slab plum interaction,mantle convection,samoan plume,yellowstone plume,dynamic topography
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease (ADVANCE-AD)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Sweden
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Alzheimer’s disease (AD) is the most common cause of dementia and a major global health challenge. AD has a long pre-symptomatic phase spanning several decades. The accuracy of clinical AD diagnostics is mediocre, especially in primary care. This results in suboptimal treatment and care, which is especially problematic in light of emerging anti-amyloid therapies. ADVANCE-AD aims to revolutionize AD diagnostics and prognostics and fast-track the development of new effective therapies by using novel blood-based biomarkers forbeta-amyloid, tau, neurodegeneration and neuroinflammation. First, my team will transform the clinical work-up of symptomatic AD patients globally by developing scalable, non-invasive and cost-effective diagnostic and prognostic algorithms based on novel blood-based biomarkers and digital tools. Second, disease-modifying therapies should be initiated already in the pre-symptomatic phase to be very effective. My team will therefore develop cost-effective diagnostic algorithms to identify AD pathology in individuals without cognitive symptoms, and prognostic algorithms to detect those most likely to develop symptoms and thereby benefit from new therapies. These new algorithms will then be used to recruit individuals into a pre-symptomatic trial-ready cohort to efficiently evaluate new anti-AD drugs. Third, new drug candidates for our trial-ready cohort will be identified using large-scale analyses of the novel AD-related biomarkers in biobanked longitudinal blood samples from already performed randomized placebo-controlled trials. Using this high risk/high-gain approach, we will evaluate if different classes of existing drugs (e.g. statins, GLP-1 agonists, anti-inflammatory agents) can halt development of AD and neurodegeneration. Finally, a novel genetic anti-tau treatment will be evaluated in this trial-ready cohort. ADVANCE-AD builds on world-leading research and will likely result in breakthroughs in early diagnostics and treatments for AD.

Keywords: alzheimer s disease,biomarkers,plasma,tau,treatments,pre symptomatic
Unruly entanglements of sociomaterial change, knowledge, and power in energy frontiers (UNRULY)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Human Mobility, Environment, and Space
Panel description: Human geography, demography, health, susta inability science, territorial planning, spatial analysis
Countries involved: Norway
Call: ERC ADVANCED GRANTS (ERC-2023-ADG, 2023)
Start date: 2024-12-01
End date: 2029-11-30
Duration (months): 60.0
Total project cost (EUR): 2496601.0
EU funding (EUR): 2496601.0
Participants: 1
Project status: SIGNED

Energy is foundational to climate change adaptation and mitigation goals, but the present moment requires more than clean power plants. Energy frontiers are entangled in uncertain geopolitics, injustices, environmental change, and development efforts, raising the stakes for research on sociomaterial change. UNRULY aims to create a paradigm-shifting, new analytical framework of change, one that transcends disciplinary conceptual boundaries to hold the social and the material together theoretically and methodologically. Grounded in justice issues, the project has four objectives: innovate a new theory of sociomaterial change through ‘unruliness’; create new research methods to analyse sociomaterial change; advance empirical research on energy frontiers; and reframe what requires governing in unruly contexts. UNRULY creates a novel theoretical basis for understanding how power materialises through uncertainties, knowledges, uneven social relations, (colonialism, racism, class, patriarchy) and governance challenges. Methodologically, the project is carefully designed to build towards the higher-risk, high-gain dimensions. The work will contribute fresh insights on hydropower energy frontiers in two case studies (Nepal and Zambia) and develop new methods capable of analysing variables and processes defined as inherently sociomaterial. The results aim to tease out an analytical basis for democratic debate on the tension between efforts at prediction and governing change, and uncertainty and unruliness which can derail those efforts. The PI will lead an international, cross-disciplinary research team, comprised of two postdoctoral fellows, two PhD candidates, three research affiliates, and an advisory board of international academic leaders, boldly challenging existing research conventions on sociomaterial change and reimagining novel approaches to our shared planetary crisis.

Keywords: energy,power,sociomaterial change,political ecology,plural research designs,methodological innovation,environmental governance
Fate of reduced organic sulfur (Fate roS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: France,Canada
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-11-01
End date: 2025-10-31
Duration (months): 36.0
Total project cost (EUR): 291785.28
EU funding (EUR): 291785.28
Participants: 3
Project status: CLOSED

Arctic suffers of the global warming and as a consequence ground- and surface waters are more and more mixed, increasing microbial activities. Because roS are present in all living organisms as amino acids (i.e. cysteine and methionine), increasing microbial activities induce increasing production of reduced organic sulfur (roS) and organic matter (OM). Some metals and metalloids (Me) have a large affinity for roS (i.e. Pt2+, Pd2+, Hg2+, Cd2+, As(OH)3, Sb(OH)3), leading to the formation of ros-Me complexes. The presence of roS modifies thus the fate, speciation (i.e. all chemical and physical forms), bioaccumulation and toxicity of Me. Rate of roS and rate of Me are interconnected: aquatic living organisms produce roS in response to Me stress, in order to modify the speciation of Me, which in turn modifies the bioaccumulation and toxicity of Me. Despite the interconnections of Me and S biogeochemical cycles, such roS-Me forms are neither quantified (i) in the environment (i.e. water), (ii) nor in laboratory ecotoxicological studies, (iii) or in ecotoxicological modelling, and (iv) only partly in laboratory geochemical experiments (i.e. only the model I developed in 2015 consider As association to reduced S of OM). In Fate roS, we will elucidate roS-Me associations through analytical developments dedicated to natural waters, which will be able to quantify roS speciation in boreal waters (including high Arctic). Thanks to a coupling of original experimental and spectroscopic results, a toxicogeochemical model will then be developed to predict the toxicity of Me and Me-roS. A successful scientific and training project is expected due to a cleverly thought 3-way-transfer of complementary skills in between me, my supervisors of the host institution (HI) and the partner institution (PI) such as: Me geochemistry knowledge (me), S biogeochemical cycle and fate in arctic context (PI) and finally Me toxicity (HI).

Keywords: sulfur,arctic,metal,metalloid,speciation,cysteine,methionine
Liquid-Liquid Phase Separation and Translational Control in the developing cortex and its implications for Neurodevelopmental Disorders. (Neuro-Phase)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Greece,Belgium
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-05-01
End date: 2027-04-30
Duration (months): 24.0
Total project cost (EUR): 181423.68
EU funding (EUR): 181423.68
Participants: 2
Project status: SIGNED

Neurodevelopmental disorders (NDDs), including Fragile X Syndrome (FXS), are a heterogeneous group of conditions leading to difficulties with speech, learning and other neurological functions greatly affecting patients and healthcare, societal, and educational systems. The rising prevalence of NDDs highlights the urgent need to understand their origins, often rooted in early cortical development. In humans, the cerebral cortex, responsible for cognitive functions like language and learning, is susceptible to disruptions during early brain development, a process tightly regulated by neuronal growth and protein synthesis. The coordination of biochemical events in eukaryotic cells, including protein synthesis, is facilitated by compartmentalizing key molecules either into organelles or as membraneless condensates via liquid-liquid phase separation (LLPS). LLPS is crucial for neurotransmission, memory, and synaptic plasticity. The fragile X messenger ribonucleoprotein 1 (FMRP) has been shown to undergo LLPS with the translation factor 4E-BP2 (eukaryotic initiation factor 4E binding protein 2), a key regulator in the mechanistic target of rapamycin (mTOR) signaling pathway implicated in both autism and FXS and the development of cortical outer radial glia. The Neuro-Phase project will investigate the role of LLPS and the molecular and cellular mechanisms involved in NDDs and more specifically the role of 4E-BP2-FMRP LLPS interaction in translational control and early human brain development which has yet to be explored. To test this hypothesis, the Neuro-Phase project will use innovative biological models, including human induced pluripotent stem cell-derived brain organoids and organotypic cultures of post-mortem human embryonic cortical explants. This project will provide critical insights into the pathogenesis of NDDs by identifying potential therapeutic targets, that leverage cellular intrinsic mechanisms like LLPS, to mitigate or prevent these conditions.

Keywords: neurodevelopmental disorders,neurobiology,early human brain development,translational control,corticogenesis,fragile x syndrome,asd,liquid liquid phase separation